Preemptive Antiviral Therapy for Hepatitis B in Radiotherapy Patients
Yes, patients with evidence of hepatitis B infection undergoing radiotherapy should receive preemptive antiviral prophylaxis, particularly when radiotherapy is combined with other cancer treatments or when treating hepatocellular carcinoma.
Risk of HBV Reactivation with Radiotherapy
Radiotherapy poses a real risk for hepatitis B virus (HBV) reactivation, though the evidence base is more limited compared to systemic chemotherapy. Research demonstrates that HBV reactivation occurs in 12.7-33.3% of patients receiving radiotherapy without antiviral prophylaxis 1. The risk is particularly elevated when:
- Radiotherapy is combined with TACE (transarterial chemoembolization) - this combination increases reactivation risk 5-fold 1
- Treating hepatocellular carcinoma with underlying HBV infection
- Using higher radiation doses or prolonged treatment courses
Who Needs Prophylaxis
Chronic HBV Infection (HBsAg-positive)
All HBsAg-positive patients undergoing radiotherapy should receive antiviral prophylaxis 2. The 2020 ASCO guidelines explicitly state that patients with chronic HBV receiving any systemic anticancer therapy should receive prophylaxis, and while radiotherapy is not specifically systemic therapy, the evidence shows comparable reactivation risks 1, 3.
Past HBV Infection (HBsAg-negative, anti-HBc-positive)
For patients with past HBV infection, the approach depends on the clinical context:
- High-risk scenarios (combined RT with TACE, treating HCC): Start prophylaxis 1
- Standard radiotherapy alone: Close monitoring with HBsAg and ALT every 3 months is acceptable, with immediate antiviral therapy if reactivation occurs 2
Screening Before Radiotherapy
All patients should be tested before radiotherapy with:
- Hepatitis B surface antigen (HBsAg)
- Hepatitis B core antibody (anti-HBc, total IgG)
- Antibody to hepatitis B surface antigen (anti-HBs)
Do not delay radiotherapy while awaiting results 2, 4.
Antiviral Regimen
Preferred agents with high resistance barrier:
- Entecavir
- Tenofovir disoproxil fumarate (TDF)
- Tenofovir alafenamide (TAF)
Avoid lamivudine due to resistance concerns 2, 4.
Treatment Duration
- Start: Before or simultaneously with radiotherapy initiation 2
- Continue: Throughout radiotherapy AND for at least 12 months after completion 2
- For combined RT-TACE: May require 18 months post-treatment 2
Monitoring Protocol
During Prophylaxis:
- Baseline HBV DNA and ALT before radiotherapy
- HBV DNA and ALT every 6 months during antiviral therapy 2
After Stopping Antivirals:
- Monitor ALT monthly for first 3 months, then every 3 months thereafter 2
- Hepatitis flares can occur after discontinuation of prophylaxis
Evidence Quality and Clinical Pitfalls
The evidence supporting prophylaxis in radiotherapy comes primarily from observational studies 1, 3 rather than randomized trials, but the data are compelling: antiviral prophylaxis reduced HBV reactivation from 33.3% to 7.5% and hepatitis from 14.8% to 3.8% 1.
Common pitfalls to avoid:
- Assuming radiotherapy alone is "low risk" - it's not, especially for HCC patients
- Using lamivudine instead of high-barrier agents
- Stopping antivirals too early (must continue 12 months post-treatment)
- Failing to monitor for withdrawal flares after stopping prophylaxis
- Not screening patients before starting radiotherapy
The strongest evidence shows that absence of antiviral treatment increases reactivation risk 8-fold 1, making prophylaxis a critical component of safe radiotherapy delivery in HBV-infected patients.